Stephen D. Gillies

Immunology and Microbiology · Life Sciences

55h-index12.2kcitations246works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(88), Neuroblastoma Research and Treatments(69), Monoclonal and Polyclonal Antibodies Research(67), CAR-T cell therapy research(66), Cancer Immunotherapy and Biomarkers(39)

Publications244 total

Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
2025Open Access
Figure S3 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Data from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Supplemental Figure Legends from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Data from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Figure S3 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Figure S2 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Supplemental Figure Legends from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Figure S2 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Figure S1 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Figure S1 from Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites
2023Open Access
Table S4 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
2023Open Access
SUPPLEMENTAL MATERIALS from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
2023Open Access
Data from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
2023Open Access
Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
2023Open Access
Data from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
2023Open Access
SUPPLEMENTAL MATERIALS from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
2023Open Access
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Ralph A. Reisfeld(16), Paul M. Sondel(15), Jacquelyn A. Hank(14), Kin-Ming Lo(10), Jacek Gan(7), Holger N. Lode(7), Rong Xiang(5), Alexander L. Rakhmilevich(5), Robert C. Seeger(4), Mark R. Albertini(4), Jens C. Eickhoff(4), John M. Maris(4), Barbara M. Mueller(4), R. Reisfeld(4), KyungMann Kim(4), Michael Super(4), Alice L. Yu(4), Yan Lan(4), Rupert Handgretinger(3), Susumu Tonegawa(3)